OSA Increases CKD Risk in Recovered Acute Cardiogenic Pulmonary Edema
Obstructive sleep apnea increases the risk for chronic kidney disease in patients who have recovered from an episode of acute cardiogenic pulmonary edema.
Obstructive Sleep Apnea
Obstructive Sleep Apnea Symptom Subtypes Identified Using Novel Algorithm
A simple, efficient algorithm has been developed that will help to classify symptom subtypes among patients with obstructive sleep apnea based on only 6 symptom items.
High Prevalence of Obstructive Sleep Apnea in Children With Suspected ROHHAD Syndrome
Researchers sought to explore the clinical presentations of sleep-disordered breathing in patients with suspected ROHHAD.
Bariatric Surgery May Decrease Long-Term OSA Severity in Some Patients With Obesity
Researchers discovered that bariatric surgery led to a significant decrease in BMI, waist circumference, neck circumference, and AHI compared with in the optimized clinical treatment group.
Common Treatment Emergent Adverse Effects of Solriamfetol in Patients With OSA and Narcolepsy
Common early onset treatment-emergent adverse events associated with solriamfetol include headache, anorexia, and nausea in patients with obstructive sleep apnea and narcolepsy.
Polysomnographic Thresholds of Limited Use in Pediatric OSA
Polysomnographic resolution of obstructive sleep apnea and changes in polysomnographic severity of OSA in children account for a small but significant proportion of changes in symptoms and disease-specific quality of life.
Link Between Lesion Location and Obstructive Sleep Apnea in Multiple Sclerosis
The risk for development of obstructive sleep apnea (OSA) and the severity of disease in patients with multiple sclerosis (MS) may be affected by the location of the lesions.
CPAP vs NIV for Ambulatory Patients With Obesity Hypoventilation Syndrome
Continuous positive airway pressure may be a preferred alternative to noninvasive ventilation as first-line therapy in stable ambulatory patients with obesity hypoventilation syndrome and concurrent severe obstructive sleep apnea.
CPAP Alleviates Depression Symptoms in Sleep Apnea Patients
Continuous positive airway pressure treatment reduces depression symptoms in patients with coexisting obstructive sleep apnea and cardiovascular disease.
Wakefulness Promoter Sunosi Designated Schedule IV Controlled Substance
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.
Next post in Sleep Disorders
